GalXC Plus Logo (WIPO, 07/14/2021)
WIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The International trademark GalXC Plus was filed as Figurative mark on 07/14/2021 at the World Intellectual Property Organization.
Logodesign (Wiener Klassifikation)
#Triangles, lines forming an angle #Letters presenting a special form of writing #Colours #Several triangles, juxtaposed, joined or intersecting #Series of letters in different dimensions #Three predominant colours
| Trademark form | Figurative mark |
| File reference | 1621515 |
| Countries | 
|
| Base trademark |
No. 90474748,
January 19, 2021
|
| Application date | July 14, 2021 |
| Expiration date | July 14, 2031 |
Trademark owner
87 Cambridgepark Drive
Cambridge MA 02140
US
Cambridge MA 02140
US
Trademark representatives
Two Commerce Square,
2001 Market Street,
US
goods and services
05
Oligonucleotide compounds for use in targeted pharmaceutical
therapies for the treatment of rare diseases, genetic
disorders, cardiovascular diseases, and viral infections;
oligonucleotide delivery agents for use in targeted
pharmaceutical therapies for the treatment of rare diseases,
genetic disorders, cardiovascular diseases, and viral
infections; oligonucleotide compounds for use in the
targeted delivery of RNAi therapy; oligonucleotide delivery
agents consisting of compounds that facilitate the delivery
of a wide range of pharmaceutical and therapeutic agents
intravenously or subcutaneously for use in targeted
pharmaceutical therapies for a wide range of medical
purposes; drug delivery agents consisting of oligonucleotide
compounds that facilitate the delivery of a wide range of
pharmaceutical based therapies
42
Research and development of oligonucleotide compounds for
use in targeted pharmaceutical therapies for the treatment
of rare diseases, genetic disorders, cardiovascular
diseases, and viral infections; research and development of
pharmaceutical preparations for the treatment of disorders
outside the liver; research and development of
oligonucleotide compounds for targeted gene silencing;
research and development of oligonucleotide drug delivery
platforms for use in the treatment of rare diseases, genetic
disorders, cardiovascular diseases, and viral infections
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| May 10, 2023 | 2023/19 Gaz | CA | Rejection |
| December 15, 2022 | 2022/51 Gaz | JP | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| June 2, 2022 | 2022/22 Gaz | JP | Rejection |
| March 10, 2022 | 2022/10 Gaz | EM | Rejection |
| February 22, 2022 | 2022/8 Gaz | CN | Rejection |
| February 2, 2022 | 2022/5 Gaz | GB | Rejection |
| January 12, 2022 | 2022/3 Gaz | AU | Rejection |
| July 14, 2021 | 2021/40 Gaz | US | Registration |
ID: 141621515